Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
Real World Study of PEGylated Recombinant Human Granulocyte Stimulating Factor(PEG-rhG-CSF) in Prevention of Chemotherapy-induced Neutropenia
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Voraussichtlich)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Sun Guoping
- Telefonnummer: 13805609309
- E-Mail: sunguoping@ahmu.edu.cn
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Patients' age≥18 years old, male or female
- Diagnosis of non-myeloid malignant solid tumors
- Patients are planned to perform chemotherapy and preventive use the PEG-rhG-CSF or preventive or therapeutic use of rhG-CSF after chemotherapy
- Patients' mental status are well, could understand the study and willing to participate the study, sign the informed consent form
- The investigator believes that patients can benefit from this study
Exclusion Criteria:
- Patients who have been confirmed to be allergic to Jinyouli® or rhG-CSF or its excipients
- Pregnant or lactating women and women who plan to be pregnant during clinical observation
- Other patients that the doctor believe not suitable for inclusion
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
PEG-rhG-CSF group
This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle.
The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
|
PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
Andere Namen:
|
|
rhG-CSF group
This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cost-Effectiveness
Zeitfenster: through the chemotherapy cycles of PEG-rhG-CSF or rhG-CSF treatment,an average of 3 month
|
Based on the results of the incidence of febrile neutropenia(FN) and the cost perFN in each group, the incremental cost-effectiveness ratio were estimated using the following formula: (CostA-CostB)/(OutcomeA-OutcomeB)
|
through the chemotherapy cycles of PEG-rhG-CSF or rhG-CSF treatment,an average of 3 month
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The incidence of febrile neutropenia
Zeitfenster: From date of randomization until the date of the study completion,an average of 3 month
|
Febrile neutropenia (FN) is defined as oral temperature >38.3 ℃(under arm temperature >38.1 ℃) or continuous measurement of oral temperature >38℃(under arm temperature >37.8℃) in 2h, and absolute neutrophil count(ANC) <0.5×10^9/L, or expected to be <0.5×10^9/L
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The incidence of grade IV neutropenia
Zeitfenster: From date of randomization until the date of the study completion,an average of 3 month
|
Grade IV neutropenia is defined as the absolute neutrophil count(ANC)<0.5×10^9/L
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The duration of grade IV neutropenia in every chemotherapy cycle
Zeitfenster: From date of randomization until the date of the study completion,an average of 3 month
|
Defined as days when the ANC<2.0×10^9/L
occurs to the time when the ANC≥2.0×10^9/L,
take the median
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The incidence of the chemotherapy delay
Zeitfenster: From date of randomization until the date of the study completion,an average of 3 month
|
Chemotherapy delay is defined as the delay in starting the next planned chemotherapy for more than 3 days.
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The duration of the chemotherapy delay in every chemotherapy cycle
Zeitfenster: From date of randomization until the date of the study completion,an average of 3 month
|
The duration of the chemotherapy delay in every chemotherapy cycle
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The incidence of the dose reduction
Zeitfenster: From date of randomization until the date of the study completion,an average of 3 month
|
The incidence of the reduction of planned dose of chemotherapy
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
Relative chemotherapy dose intensity in every chemotherapy cycle
Zeitfenster: From date of randomization until the date of the study completion,an average of 3 month
|
Relative chemotherapy dose intensity is defined as the actual chemotherapy dose the patient used divided by the planned chemotherapy dose,or the actual chemotherapy time divided by the planned chemotherapy time
|
From date of randomization until the date of the study completion,an average of 3 month
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of adverse events
Zeitfenster: From date of randomization until the date of the study completion,an average of 3 month
|
All adverse events will be recorded from the time of patients signing the informed consent form up to 30 days after the last Intervention drug is applied.
the adverse event that associated with the study drug will be specially recorded.
|
From date of randomization until the date of the study completion,an average of 3 month
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Primärer Abschluss
Studienabschluss (Voraussichtlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CSPC-JYL-RWS-07
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .